Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L, ECHELON-2 Study Group.
Lancet. 2018 Dec 3; pii: S0140-6736(18)32984-2. doi: 10.1016/S0140-6736(18)32984-2.

PMID:
    30522922
    [PubMed - as supplied by publisher]
Related citations


Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol. 2018 Nov 30; pii: S1470-2045(18)30864-7. doi: 10.1016/S1470-2045(18)30864-7.

PMID:
    30518502
    [PubMed - as supplied by publisher]
Related citations


Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol. 2018 Dec; 5(12)e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
    30501868
    [PubMed - in process]
Related citations


Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC
N Engl J Med. 2018 Dec 1; doi: 10.1056/NEJMoa1812836.

PMID:
    30501481
    [PubMed - as supplied by publisher]
Related citations


CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM
N Engl J Med. 2018 Nov 1; 379(18)1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
    30380386
    [PubMed - indexed for MEDLINE]
Related citations


Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A
Leukemia. 2018 Oct 12; doi: 10.1038/s41375-018-0276-9.

PMID:
    30315239
    [PubMed - as supplied by publisher]
Related citations


Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
Strati P, Fanale M, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ
Haematologica. 2018 Sep 6; pii: haematol.2018.199844. doi: 10.3324/haematol.2018.199844.

PMID:
    30190343
    [PubMed - as supplied by publisher]
Related citations


Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, RELEVANCE Trial Investigators.
N Engl J Med. 2018 Sep 6; 379(10)934-947. doi: 10.1056/NEJMoa1805104.

PMID:
    30184451
    [PubMed - indexed for MEDLINE]
Related citations


Chimeric Antigen Receptor T-Cell Therapy.
Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST
J Natl Compr Canc Netw. 2018 Sep; 16(9)1092-1106. doi: 10.6004/jnccn.2018.0073.

PMID:
    30181421
    [PubMed - in process]
Related citations


<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R
Cancer Discov. 2018 Oct; 8(10)1258-1269. doi: 10.1158/2159-8290.CD-18-0743.

PMID:
    30154192
    [PubMed - in process]
Related citations


CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL
Blood. 2018 Sep 6; 132(10)1013-1021. doi: 10.1182/blood-2018-01-827246.

PMID:
    30049811
    [PubMed - in process]
Related citations


Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes.
Drylewicz MR, Watkins MP, Shetty AS, Lin MF, Salter A, Bartlett NL, Middleton WD, Yano M
J Ultrasound Med. 2018 Jul 25; doi: 10.1002/jum.14724.

PMID:
    30043431
    [PubMed - as supplied by publisher]
Related citations


CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP, Bartlett NL
Expert Opin Investig Drugs. 2018 Jul; 27(7)601-611. doi: 10.1080/13543784.2018.1492549.

PMID:
    29940805
    [PubMed - indexed for MEDLINE]
Related citations


Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P
Haematologica. 2018 Sep; 103(9)1502-1510. doi: 10.3324/haematol.2018.192328.

PMID:
    29880603
    [PubMed - in process]
Related citations


Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM
N Engl J Med. 2018 Apr 12; 378(15)1396-1407. doi: 10.1056/NEJMoa1801445.

PMID:
    29641966
    [PubMed - indexed for MEDLINE]
Related citations


Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR
Blood. 2018 May 10; 131(19)2120-2124. doi: 10.1182/blood-2017-12-821009.

PMID:
    29507077
    [PubMed - in process]
Related citations


Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Mehta-Shah N, Bartlett NL
Blood. 2018 Apr 12; 131(15)1698-1703. doi: 10.1182/blood-2017-09-772681.

PMID:
    29500171
    [PubMed - in process]
Related citations


SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP, Fanale MA, Bartlett NL
Clin Lymphoma Myeloma Leuk. 2018 Feb; 18(2)81-90. doi: 10.1016/j.clml.2018.01.001.

PMID:
    29366607
    [PubMed - in process]
Related citations


Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
Blood. 2018 Mar 15; 131(11)1183-1194. doi: 10.1182/blood-2017-10-811224.

PMID:
    29229594
    [PubMed - in process]
Related citations


Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med. 2017 Dec 28; 377(26)2531-2544. doi: 10.1056/NEJMoa1707447.

PMID:
    29226797
    [PubMed - indexed for MEDLINE]
Related citations